MEMLX
Price
$14.46
Change
-$0.12 (-0.82%)
Updated
Nov 13 closing price
RNWFX
Price
$81.74
Change
-$0.65 (-0.79%)
Updated
Nov 13 closing price
Ad is loading...

MEMLX vs RNWFX

Header iconMEMLX vs RNWFX Comparison
Open Charts MEMLX vs RNWFXBanner chart's image
Morgan Stanley Inst EMkts Ldrs C
Price$14.46
Change-$0.12 (-0.82%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$81.74
Change-$0.65 (-0.79%)
VolumeN/A
CapitalizationN/A
MEMLX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MEMLX vs. RNWFX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEMLX is a Buy and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.3B vs. MEMLX (232M). RNWFX pays higher dividends than MEMLX: RNWFX (1.51) vs MEMLX (0.00). MEMLX was incepted earlier than RNWFX: MEMLX (10 years) vs RNWFX (23 years). MEMLX is a more actively managed with annual turnover of: 54.00 vs. RNWFX (32.00). RNWFX has a lower initial minimum investment than MEMLX: RNWFX (250) vs MEMLX (1000). MEMLX (17.30) and RNWFX (16.65) have marching annual gain over last year. MEMLX return over 5 years is better than : 22.73 vs. RNWFX (20.63).
MEMLXRNWFXMEMLX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence10 years23 years-
Gain YTD7.9209.53283%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets232M62.3B0%
Annual Yield % from dividends0.001.51-
Returns for 1 year17.3016.65104%
Returns for 3 years-28.91-12.40233%
Returns for 5 years22.7320.63110%
Returns for 10 yearsN/A44.31-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DYN29.381.25
+4.44%
Dyne Therapeutics
DGX161.701.53
+0.96%
Quest Diagnostics
LVO0.89-0.02
-1.97%
LiveOne
PTLO12.13-0.27
-2.18%
Portillo's
ENSC0.67-0.02
-2.63%
Ensysce Biosciences